Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis

被引：1

作者：

Dimopoulos, Meletios A. ^{[1
]}

Leleu, Xavier ^{[2
]}

Moreau, Philippe ^{[3
]}

Attal, Michel ^{[4
]}

Richardson, Paul G. ^{[5
]}

Liberati, Anna Marina ^{[6
]}

Harrison, Simon J. ^{[7
]}

Prince, H. Miles ^{[8
]}

Ocio, Enrique M. ^{[9
]}

Assadourian, Sylvie ^{[10
]}

Campana, Frank ^{[11
]}

Malinge, Laure ^{[12
]}

van de Velde, Helgi ^{[13
]}

Yong, Kwee ^{[14
]}

机构：

[1] Univ Athens, Sch Med, Athens, Greece

[2] CHU Miletrie, Poitiers, France

[3] Univ Poitiers, Dept Hematol, Ctr Hosp Univ, Poitiers, France

[4] Univ Canc Ctr Toulouse, Inst Natl Sante, Toulouse, France

[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[6] Univ Perugia, Santa Maria Hosp, Oncol Hematol, Perugia, Italy

[7] Univ Melbourne, Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[8] Univ Melbourne, Epworth Healthcare, Melbourne, Vic, Australia

[9] Hosp Univ Marques Valdecilla, Santander, Spain

[10] Sanofi R&D, Paris, France

[11] Sanofi Genzyme Oncol, Cambridge, MA USA

[12] Aixial Sanofi, Boulogne, France

[13] Sanofi, Cambridge, MA USA

[14] Univ Coll London Hosp NHS Fdn Trust, London, England

来源：

关键词：

CD38; Multiple myeloma; Renal impairment;

D O I：

10.1016/j.clml.2019.09.420

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-094

引用

页码：E254 / E254

页数：1